Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Class A common stock, par value $0.001 per share
-
Shares outstanding
-
66,027,379
-
Total 13F shares
-
12,063,607
-
Share change
-
-541,150
-
Total reported value
-
$172,475,348
-
Price per share
-
$14.32
-
Number of holders
-
30
-
Value change
-
-$5,229,083
-
Number of buys
-
14
-
Number of sells
-
18
Institutional Holders of Immuneering Corp - Class A common stock, par value $0.001 per share (IMRX) as of Q3 2022
As of 30 Sep 2022,
Immuneering Corp - Class A common stock, par value $0.001 per share (IMRX) was held by
30 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
12,063,607 shares.
The largest 10 holders included
PRICE T ROWE ASSOCIATES INC /MD/, Cormorant Asset Management, LP, CITADEL ADVISORS LLC, BlackRock Inc., VANGUARD GROUP INC, T. Rowe Price Investment Management, Inc., FMR LLC, BUCKINGHAM STRATEGIC WEALTH, LLC, GEODE CAPITAL MANAGEMENT, LLC, and TD ASSET MANAGEMENT INC.
This page lists
30
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.